Prometheus Biosciences, Inc., (RXDX) News
Filter RXDX News Items
RXDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RXDX News Highlights
- For RXDX, its 30 day story count is now at 4.
- Over the past 23 days, the trend for RXDX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SAGE are the most mentioned tickers in articles about RXDX.
Latest RXDX News From Around the Web
Below are the latest news stories about PROMETHEUS BIOSCIENCES INC that investors may wish to consider to help them evaluate RXDX as an investment opportunity.
Wall Street Analysts Think Prometheus Biosciences, Inc. (RXDX) Could Surge 33.49%: Read This Before Placing a BetThe mean of analysts' price targets for Prometheus Biosciences, Inc. (RXDX) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBBXBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article. |
Biotech's Blockbuster Week: 3 Stocks to WatchIn a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space. |
Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Prometheus Biosciences, Inc. (RXDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, MD, Chief Medical Officer, will present a company overview at the 41st Annual J.P. Mo |
We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, Prometheus... |
12 Best Multibagger Stocks to Buy NowIn this article, we discuss 12 best multibagger stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Multibagger Stocks to Buy Now. In this uncertain market backdrop, investors are focused on macroeconomic and geopolitical constraints and their potential effects on investment portfolios. Goldman Sachs believes the […] |
Is Prometheus Biosciences a Good Stock to Buy Right Now?This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead. |
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common StockSAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share. All of the shares to be sold in th |
Why Shares of Prometheus Biosciences Are Soaring This WeekThe clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy. |